Miola C - Search Results

1

Inhibition by salbutamol of GHRH-induced GH release in type 1 diabetes mellitus.

Martina V, Miola C, Maccario M, Talliano M, Arvat E, Ghigo E, Camanni F. Martina V, et al. Among authors: miola c. Horm Metab Res. 1992 Nov;24(11):520-3. doi: 10.1055/s-2007-1003379. Horm Metab Res. 1992. PMID: 1333441

2

Arginine abolishes the inhibitory effect of glucose on the growth hormone response to growth hormone-releasing hormone in man.

Ghigo E, Miola C, Aimaretti G, Valente F, Procopio M, Arvat E, Yin-Zhang W, Camanni F. Ghigo E, et al. Among authors: miola c. Metabolism. 1992 Sep;41(9):1000-3. doi: 10.1016/0026-0495(92)90127-V. Metabolism. 1992. PMID: 1355580

3

Long-term follow-up of 'cured' prolactinoma patients after successful adenomectomy.

Ciccarelli E, Ghigo E, Miola C, Gandini G, Muller EE, Camanni F. Ciccarelli E, et al. Among authors: miola c. Clin Endocrinol (Oxf). 1990 May;32(5):583-92. doi: 10.1111/j.1365-2265.1990.tb00901.x. Clin Endocrinol (Oxf). 1990. PMID: 2114241

4

Double blind randomized study using oral or injectable bromocriptine in patients with hyperprolactinaemia.

Ciccarelli E, Grottoli S, Miola C, Avataneo T, Lancranjan I, Camanni F. Ciccarelli E, et al. Among authors: miola c. Clin Endocrinol (Oxf). 1994 Feb;40(2):193-8. doi: 10.1111/j.1365-2265.1994.tb02467.x. Clin Endocrinol (Oxf). 1994. PMID: 8137517 Clinical Trial.

5

Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.

Ciccarelli E, Giusti M, Miola C, Potenzoni F, Sghedoni D, Camanni F, Giordano G. Ciccarelli E, et al. Among authors: miola c. J Clin Endocrinol Metab. 1989 Oct;69(4):725-8. doi: 10.1210/jcem-69-4-725. J Clin Endocrinol Metab. 1989. PMID: 2570790

6

Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.

Ciccarelli E, Miola C, Grottoli S, Avataneo T, Lancranjan I, Camanni F. Ciccarelli E, et al. Among authors: miola c. J Clin Endocrinol Metab. 1993 Feb;76(2):484-8. doi: 10.1210/jcem.76.2.8432794. J Clin Endocrinol Metab. 1993. PMID: 8432794

7

Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions.

Gianotti L, Broglio F, Aimaretti G, Arvat E, Colombo S, Di Summa M, Gallioli G, Pittoni G, Sardo E, Stella M, Zanello M, Miola C, Ghigo E. Gianotti L, et al. Among authors: miola c. J Endocrinol Invest. 1998 Feb;21(2):115-21. doi: 10.1007/BF03350325. J Endocrinol Invest. 1998. PMID: 9585386

8

Activity of GH/IGF-I axis in trauma and septic patients during artificial nutrition: different behavior patterns?

Pittoni G, Gallioi G, Zanello M, Gianotti L, Boghen MF, Colombo S, Broglio F, Santoro C, Davià G, Papini MG, Destefanis S, Minuto F, Miola C, Ghigo E. Pittoni G, et al. Among authors: miola c. J Endocrinol Invest. 2002 Mar;25(3):214-23. doi: 10.1007/BF03343993. J Endocrinol Invest. 2002. PMID: 11936462

9

Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia.

Ciccarelli E, Miola C, Avataneo T, Camanni F, Besser GM, Grossman A. Ciccarelli E, et al. Among authors: miola c. Fertil Steril. 1989 Dec;52(6):930-5. doi: 10.1016/s0015-0282(16)53154-9. Fertil Steril. 1989. PMID: 2591571 Free article.

10

Natural killer activity in hyperprolactinemic patients.

Matera L, Ciccarelli E, Cesano A, Veglia F, Miola C, Camanni F. Matera L, et al. Among authors: miola c. Immunopharmacology. 1989 Sep-Oct;18(2):143-6. doi: 10.1016/0162-3109(89)90067-2. Immunopharmacology. 1989. PMID: 2807874

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters